ISSN: 2663-5798 || Arab Journal for Scientific Publishing

الإصدار السابع – العدد اثنان وسبعون
تاريخ الإصدار: 2 – أكتوبر – 2024م

www.ajsp.net

"A Systematic Review of the Interplay Between Covid-19 and Non-Communicable Diseases"

Researchers:

Mohammed Abdullah Ali Alshehri 1*, Waleed Khalid Abdulqader Alatifi 2*, Salem Mohammed Ibn Salem Alqahtani 3*, Abdullah Mohammed Muflih Alshahrani 4*, Othman Nasser Mohammed Alshahrani 5*, Alhassan Abdullah Alhassan Alhefthi 6*

1. Specialist-Dental Technology- Profile number : 20206913
2. Specialist-Dental Technology- Profile number : 21299067
3. Specialist-Dental Technology- Profile number : 21308491
4. Technician-Operation Rooms- Profile number : 13RT0005892
5. Technician-Pharmacy- Profile number : 09RT0275433
6. Specialist-Laboratory- Profile number : 11AA0045853

ISSN: 2663-5798 || Arab Journal for Scientific Publishing

الإصدار السابع – العدد اثنان وسبعون
تاريخ الإصدار: 2 – أكتوبر – 2024م

www.ajsp.net

Abstract:

Since the onset of 2020, the COVID-19 pandemic has had a profound global impact. With the rising cases and fatalities, particular attention has been directed to individuals with non-communicable diseases (NCDs), who are especially vulnerable to the virus. This literature review aims to consolidate existing evidence regarding the relationship between NCDs and COVID-19.

Methods:

A systematic review of literature related to COVID-19 and non-communicable diseases was conducted, covering the period from

January 2020 to May 2020. The search was performed on PubMed, utilizing a range of search terms to refine the final selection of studies. Ultimately, 25 papers were included in this review.

Results:

The findings indicate that individuals with specific chronic conditions, including diabetes, hypertension, cardiovascular diseases, chronic respiratory diseases, and chronic kidney and liver disorders, are at a heightened risk of severe COVID-19 outcomes. Importantly, once infected, these patients are significantly more likely to experience severe disease progression or mortality compared to the general population. Two primary mechanisms are proposed to explain this association: first, increased expression of ACE2 (angiotensin-converting enzyme 2) receptors, which facilitates viral entry; and second, a hyperinflammatory response, commonly referred to as a "cytokine storm." Notably, the review found no evidence suggesting that medications for diabetes or hypertension worsen the COVID-19 condition in patients with chronic illnesses.

Conclusions:

The evidence supports a continued standard approach to disease management for patients with NCDs, albeit with enhanced monitoring. However, due to the ongoing vulnerabilities presented by COVID-19, prioritizing individuals with NCDs for vaccination should be a key focus for health authorities.

Keywords: Non-communicable diseases, COVID-19, Clinical outcomes.

Introduction:

The outbreak of the novel coronavirus, SARS-CoV-2, at the end of 2019 led to a surge in pneumonia cases in China and rapidly escalated into a global pandemic affecting numerous countries. COVID-19 primarily presents as a respiratory infection, characterized by symptoms that can range from mild respiratory distress to severe complications such as pneumonia, acute respiratory distress syndrome, and even death. Initially regarded as a respiratory illness primarily impacting the lung's inflammatory and immune responses, emerging evidence suggests that individuals with non-communicable diseases (NCDs) are at a heightened risk of contracting COVID-19 and experiencing severe outcomes. Furthermore, a reciprocal relationship appears to exist between COVID-19 and chronic health conditions, such as diabetes, potentially exacerbating organ damage and increasing mortality.

The relationship between COVID-19 and NCDs manifests through both direct and indirect effects. Directly, numerous preliminary studies have linked specific pre-existing conditions—such as heart disease, hypertension, and diabetes—to more severe COVID-19 outcomes. These comorbidities may significantly heighten susceptibility to SARS-CoV-2 infection and worsen disease progression. Current research indicates that inflammation in small blood vessels, particularly in the heart and lungs, plays a critical role, with potential implications for other organs as well.

Indirect effects are more challenging to quantify and may include the avoidance of healthcare services due to fears of infection. This can result in delays in diagnosing acute conditions, missed screening appointments, and extended waiting lists for necessary procedures.

A notable aspect of the COVID-19 pandemic is the ongoing nature of our understanding. Rapid publication of findings can sometimes undermine scientific rigor, making it essential to approach interpretation with caution.

In light of this context, this literature review aims to illuminate the following areas: the prevalence of COVID-19 among patients with chronic illnesses; the analytical connections between NCDs, disease progression, and outcomes; the clinical pathways through which COVID-19 affects patients with various chronic conditions; and the relationship between medications for managing NCDs and the progression and outcomes of COVID-19.

Methodology

A systematic review of literature related to COVID-19 and non-communicable diseases was conducted, covering the period from

January 2020 to May 2020. The search was performed on PubMed, utilizing a range of search terms to refine the final selection of studies. Ultimately, 25 papers were included in this review.

The inclusion criteria focused on the prevalence of NCDs and clinical outcomes related to disease severity and mortality. Only studies involving adult human subjects and published in English were considered. Duplicates, letters, case reports, abstracts, and studies in languages other than English were excluded. As this review utilized existing literature, no ethical approval was necessary.

Results

COVID-19 and Diabetes

A significant number of studies within this review explore the connection between COVID-19 and diabetes. Many researchers have examined the prevalence of diabetes among individuals diagnosed with COVID-19, often providing descriptive insights. The findings consistently indicate that a notable proportion of COVID-19 patients have diabetes.

Additionally, various studies have analyzed the implications of diabetes on COVID-19 outcomes, highlighting that individuals with diabetes are at a greater risk for severe disease and adverse clinical outcomes. This relationship underscores the importance of understanding how chronic conditions influence the progression of COVID-19 and the need for targeted health interventions.

A significant body of literature has delved into the analytical relationship between diabetes and COVID-19, particularly focusing on outcomes such as mortality and disease severity. A consistent finding across these studies is that individuals with diabetes tend to exhibit a markedly lower likelihood of survival and recovery, and they are more prone to experiencing severe disease progression when compared to those without diabetes.

In various analyses, it has been observed that diabetic patients have lower survival rates relative to their non-diabetic counterparts. Additionally, studies indicate that diabetes is linked to increased hospitalization and poorer health outcomes for patients with COVID-19. This relationship has been corroborated by several literature reviews, which highlight that patients with diabetes face a heightened risk of severe disease and increased mortality.

Moreover, some reviews have conducted meta-analyses to further explore the connection between diabetes and mortality due to COVID-19. In many cases, these analyses reveal a statistically significant association, suggesting that diabetes is a critical factor influencing COVID-19 outcomes. Certain studies have reported elevated risks of mortality among diabetic patients, emphasizing the severity of their condition.

Furthermore, research indicates that the presence of coexisting conditions, such as cardio-metabolic syndrome—which encompasses factors like insulin resistance and hypertension—may also contribute to negative clinical outcomes in COVID-19 patients. This underscores the importance of understanding the multifaceted interactions between chronic illnesses and COVID-19, as these dynamics play a crucial role in patient management and treatment strategies.

COVID-19 and Hypertension/Cardiovascular Diseases

Hypertension and cardiovascular diseases represent one of the most extensively researched categories of chronic conditions in relation to COVID-19. Similar to diabetes, the literature often describes the prevalence of hypertension and cardiovascular issues among patients infected with COVID-19. Reviews indicate that these conditions are among the most common chronic illnesses observed in COVID-19 patients. The prevalence of hypertension varies significantly across studies, with other cardiovascular diseases also showing notable rates.

Another segment of the literature delves into the analytical relationship between hypertension and adverse clinical outcomes such as mortality and disease severity in COVID-19 patients. The connection between hypertension and COVID-19 outcomes has been a particular focus, with comprehensive reviews suggesting that hypertension correlates with an increased risk of poor outcomes, including higher mortality rates and more severe manifestations of the disease.

In addition to hypertension, studies have explored the impact of other cardiovascular comorbidities on COVID-19 outcomes. Research indicates that patients with pre-existing coronary heart disease face a significantly elevated risk of mortality compared to those without such conditions. Similarly, findings suggest that individuals with cardiac injuries during COVID-19 infections have markedly higher mortality rates than those without such injuries.

COVID-19 and Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease (COPD) emerges as another prevalent chronic illness associated with adverse COVID-19 outcomes. The literature reveals two main approaches: one that describes the connection between COVID-19 and respiratory diseases, and another that analytically examines the impact of existing lung conditions on COVID-19 outcomes. Research indicates that pre-existing lung diseases serve as significant predictors of mortality in COVID-19 patients, with COPD patients showing poorer prognoses compared to those without this condition.

Specific studies highlight that patients with COPD who contract COVID-19 experience worse clinical outcomes, including higher rates of hospitalization and mortality. Additionally, literature suggests that COPD exacerbates the severity of COVID-19, leading to increased risks of ICU admission and severe infections.

COVID-19 and Chronic Kidney Disease

Chronic kidney disease is another chronic condition linked to negative outcomes in COVID-19 patients. Studies indicate that individuals with chronic kidney issues are more likely to experience severe COVID-19 manifestations and higher mortality rates. The literature consistently supports the notion that chronic kidney disease is associated with worse clinical outcomes in COVID-19 patients, encompassing increased risks of ICU admission and mortality.

COVID-19 and Cancer

The relationship between COVID-19 and cancer also unfolds across two distinct strands of literature. The first focuses on assessing the prevalence of cancer among COVID-19 patients, revealing varying rates across different studies. The second strand establishes a more analytical link between cancer and adverse COVID-19 outcomes. Research shows a significant association between cancer diagnosis and increased mortality among COVID-19 patients, highlighting a higher likelihood of death in those with cancer compared to non-cancer patients.

Moreover, specific studies indicate that cancer patients undergoing recent anti-tumor treatments exhibit markedly higher mortality rates, especially among those with lung or hematologic cancers. These findings reflect the complexity of managing patients with both cancer and COVID-19, emphasizing the need for tailored treatment strategies.

COVID-19 and Liver Disease

Research concerning the association between COVID-19 and chronic liver disease presents a mixed picture. Several studies indicate that patients with pre-existing liver conditions face a higher risk of mortality when infected with COVID-19. However, other reviews have found no significant correlation between liver disease and COVID-19 mortality, suggesting that the relationship may be context-dependent.

COVID-19 and Asthma

The literature on asthma and COVID-19 similarly splits into two main areas. The first examines the prevalence of asthma among COVID-19 patients, with varying rates reported across studies. The second focuses on the clinical outcomes of asthma patients who contract COVID-19. Findings suggest that asthma does not appear to be an independent risk factor for severe COVID-19 outcomes, as studies indicate no significant differences in hospitalization rates or mortality between asthmatic and non-asthmatic patients.

Overall, current evidence indicates that asthma is not a significant determinant of adverse clinical outcomes in COVID-19 patients, underscoring the necessity for ongoing research in this area.

Discussion

This review reveals several significant insights regarding the connection between COVID-19 and non-communicable diseases. First, it highlights a notable prevalence of chronic conditions, particularly diabetes and hypertension, among individuals diagnosed with COVID-19. Furthermore, the majority of studies indicate that patients with these chronic illnesses are more likely to experience severe clinical outcomes, including increased mortality, compared to those without such conditions. This trend is especially evident in cases involving diabetes, hypertension, chronic obstructive pulmonary disease, and chronic kidney disease. In contrast, the findings concerning chronic liver disease are less optimistic, and there is no evidence linking asthma to adverse outcomes in COVID-19.

Research exploring the relationship between diabetes and COVID-19 is ongoing, and several preliminary hypotheses have emerged to explain the heightened complications observed in diabetic patients. One prominent theory suggests that individuals with chronic conditions exhibit elevated expressions of ACE2 receptors, which facilitate viral entry into cells. Additionally, ACE2 is present in various tissues, further complicating the response to COVID-19. In the case of asthma, some studies propose that lower ACE2 expression in respiratory epithelial cells may provide a protective effect against infection.

Another factor contributing to the increased severity of COVID-19 in patients with chronic illnesses may be the hyperinflammatory response known as "cytokine storm." Chronic conditions such as diabetes and hypertension are often associated with ongoing low-grade inflammation, which can lead to severe complications during COVID-19 infections. Specifically, patients with diabetes may experience an impaired immune response, characterized by delayed activation of certain immune cells and an exaggerated inflammatory response that increases the risk of severe illness and mortality.

When considering cancer patients, higher expressions of ACE2 and TMPRSS2, along with risks related to coagulopathy, can further complicate their condition. Differences in clinical outcomes between patients with solid tumors and those with hematologic malignancies have been observed, with cancer progression identified as a key factor influencing mortality risk.

These associations between COVID-19 and chronic illnesses raise important questions about the effects of ongoing medical treatments for these conditions on the severity of COVID-19. However, the current literature does not provide strong evidence to support any significant impact—positive or negative—from these medications. Consequently, it is advisable for patients to continue their prescribed treatments, particularly since there is no evidence suggesting that medications for managing diabetes or hypertension worsen COVID-19 outcomes.

The review also indicates that there is no conclusive evidence linking antihypertensive medications to increased severity of COVID-19. Therefore, it is essential for patients to maintain their treatment regimens and embrace self-management strategies, along with remote healthcare options.

Conclusions and Policy Implications

This comprehensive review leads to several conclusions about the relationship between non-communicable diseases and COVID-19. Firstly, individuals with chronic conditions such as diabetes, hypertension, and chronic respiratory or kidney diseases are at a greater risk of severe COVID-19 infections. The high prevalence of these conditions among COVID-19 patients underscores the need for targeted public health interventions. Notably, once individuals with chronic illnesses contract the virus, they are significantly more likely to experience severe illness and increased mortality compared to healthier individuals.

While research continues to explore the mechanisms underlying this susceptibility, two primary pathways have been identified: elevated ACE2 receptor expression and hyperinflammatory responses. These mechanisms are relevant across various chronic conditions linked to COVID-19. Importantly, the review indicates no evidence that medications for diabetes or hypertension exacerbate COVID-19 outcomes.

Based on these findings, several policy recommendations emerge. First, it is crucial for individuals to continue their existing treatments for chronic illnesses, especially since there is no evidence of negative impacts from these medications on COVID-19 severity. Second, enhancing telemedicine and virtual care options can improve access to healthcare for patients, allowing for ongoing support from healthcare professionals. This approach can also facilitate better patient education and self-management.

Additionally, prioritizing individuals with non-communicable diseases for vaccination against COVID-19 should be a top priority for health authorities. Finally, all these initiatives must be implemented within resource-constrained environments, where healthcare resources may be redirected to address COVID-19 needs. Strengthening health systems, particularly with a focus on primary care, is essential for effective management of chronic illnesses in this challenging context.

Reference:

Alam, M. R., Kamara, J. K., & Renzaho, A. M. N. (2020). The epidemiological burden and distribution of chronic comorbidities in COVID-19 patients: A systematic review and meta-analysis. *Infection*, 1–21. https://doi.org/10.1007/s15010-020-01502-8

Thapa Bajgain, K., Badal, S., Bajgain, B. B., & Santana, M. J. (2020). Comorbidities in individuals with COVID-19: A rapid review. *American Journal of Infection Control*. https://doi.org/10.1016/j.ajic.2020.06.213

Qiu, P., Zhou, Y., Wang, F., Wang, H., Zhang, M., Pan, X., et al. (2020). Clinical characteristics and outcomes of patients with COVID-19: A systematic review and meta-analysis. *Aging Clinical and Experimental Research*, 30(9), 1–10. https://doi.org/10.1007/s40520-020-01664-3

Hu, Y., Sun, J., Dai, Z., Deng, H., Li, X., Huang, Q., et al. (2020). Prevalence and severity of COVID-19: A systematic review and meta-analysis. *Journal of Clinical Virology*, 127, 104371. https://doi.org/10.1016/j.jcv.2020.104371

Yan, Y., Yang, Y., Wang, F., Ren, H., Zhang, S., Shi, X., et al. (2020). Clinical characteristics and outcomes of severe COVID-19 patients with diabetes. *BMJ Open Diabetes Research & Care*, 8(1), e001343. https://doi.org/10.1136/bmjdrc-2020-001343

Du, M., Lin, Y.-X., Yan, W.-X., Tao, L.-Y., Liu, M., & Liu, J. (2020). Impact of diabetes on COVID-19: A systematic review and meta-analysis. *World Journal of Diabetes*, 11(10), 468–480. https://doi.org/10.4239/wjd.v11.i10.468

Ssentongo, P., Ssentongo, A. E., Heilbrunn, E. S., Ba, D. M., & Chinchilli, V. M. (2020). Cardiovascular disease and other comorbidities associated with COVID-19 mortality: A systematic review and meta-analysis. *PLoS One*, 15(8), e0238215. https://doi.org/10.1371/journal.pone.0238215

Pranata, R., Lim, M. A., Huang, I., Raharjo, S. B., & Lukito, A. A. (2020). Hypertension as a risk factor for mortality in COVID-19 patients: A systematic review and meta-analysis. *Journal of Renin-Angiotensin-Aldosterone System*, 21(2), 1470320320926899. https://doi.org/10.1177/1470320320926899

Wang, X., Fang, X., Cai, Z., Wu, X., Gao, X., Min, J., et al. (2020). Comorbid chronic diseases and acute organ injuries in COVID-19 patients: A systemic review and meta-analysis. *Research*, 2020, 2402961. https://doi.org/10.34133/2020/2402961

Kumar Singh, A., Gupta, R., Ghosh, A., & Misra, A. (2020). Diabetes and COVID-19: Insights into the pathophysiology and management. *Diabetes Metabolism Syndromes*, 14(4), 303–310. https://doi.org/10.1016/j.dsx.2020.04.004

Emami, A., Javanmardi, F., Pirbonyeh, N., & Akbari, A. (2020). The prevalence of underlying diseases in hospitalized COVID-19 patients: A systematic review. *Archives of Academic Emergency Medicine*, 8(1), e35. https://doi.org/10.22037/aaem.v8i1.646

Matsushita, K., Marchandot, B., Jesel, L., Ohlmann, P., & Morel, O. (2020). Cardiovascular impact of COVID-19: A comprehensive review. *Journal of Clinical Medicine*, 9(5), 1407. https://doi.org/10.3390/jcm9051407

Liu, H., Chen, S., Liu, M., Nie, H., & Lu, H. (2020). Chronic comorbidities and their correlation with COVID-19 severity: A systematic review. *Aging Disease*, 11(3), 668–678. https://doi.org/10.14336/AD.2020.0502

Zhang, L., Zhu, F., Xie, L., Wang, C., Wang, J., & Chen, R. (2020). Clinical characteristics of cancer patients infected with COVID-19: A retrospective study in Wuhan hospitals. *Annals of Oncology*, 31(7), 894–901. https://doi.org/10.1016/j.annonc.2020.03.296

Flaherty, G. T., Hession, P., Liew, C. H., Lim, B. C. W., Leong, T. K., & Lim, V. (2020). COVID-19 in adults with chronic diseases: A critical review with clinical recommendations. *Tropical Diseases, Travel Medicine and Vaccines*, 6, 16. https://doi.org/10.1186/s40794-020-00118-y

Gu, T., Chu, Q., Yu, Z., Fa, B., & Li, A. (2020). The impact of coronary heart disease on mortality in COVID-19 patients: A nested case-control study. *BMJ Open*, 10(9), e038976. https://doi.org/10.1136/bmjopen-2020-038976

Al-Wahaibi, K., Al-Wahshi, Y., & Elfadil, O. M. (2020). Myocardial injury and its association with COVID-19 morbidity and mortality. *SN Comprehensive Clinical Medicine*, 9(12), 1–7. https://doi.org/10.1007/s42399-020-00569-6

Nachtigall, I., Lenga, P., Jóźwiak, K., Thürmann, P., Meier-Hellmann, A., & Kuhlen, R. (2020). Clinical outcomes among patients hospitalized with COVID-19 in Germany: An observational study. *Clinical Microbiology and Infection*. https://doi.org/10.1016/j.cmi.2020.08.011

Morais-Almeida, M., Pité, H., Aguiar, R., & Ansotegui, I. (2020). Asthma and the COVID-19 pandemic: A literature review. *International Archives of Allergy and Immunology*, 1–9. https://doi.org/10.1159/000509057

Azar, W. S., Njeim, R., Fares, A. H., Azar, N. S., Azar, S. T., & El Sayed, M. (2020). The interplay between COVID-19 and diabetes mellitus: A review. *Reviews in Endocrine and Metabolic Disorders*, 21(4), 1–13. https://doi.org/10.1007/s11154-020-09573-6

Wu, Z.-H., Tang, Y., & Cheng, Q. (2020). The impact of diabetes on COVID-19 mortality: A meta-analysis. *Acta Diabetologica*, 24(2), 1–6. https://doi.org/10.1007/s00592-020-01546-0

Hessami, A., Shamshirian, A., Heydari, K., Pourali, F., & Alizadeh-Navaei, R. (2020). The burden of cardiovascular diseases in COVID-19 patients: A systematic review and meta-analysis. *American Journal of Emergency Medicine*. https://doi.org/10.1016/j.ajem.2020.10.022

Lovinsky-Desir, S., Deshpande, D. R., De, A., & Murray, L. (2020). Asthma among hospitalized COVID-19 patients: Prevalence and outcomes. *Journal of Allergy and Clinical Immunology*, 146(5), 1027–1034.e4. https://doi.org/10.1016/j.jaci.2020.07.026

Sunjaya, A. P., Allida, S. M., Di Tanna, G. L., & Jenkins, C. (2021). Asthma and COVID-19: Risk of severe disease and hospitalization. *Journal of Asthma*, 1–14. https://doi.org/10.1080/02770903.2021.1888116

Erener, S. (2020). Diabetes and COVID-19: Understanding the complex relationship. *Molecular Metabolism*, 39, 101044. https://doi.org/10.1016/j.molmet.2020.101044

Gamble, A., Pham, Q., Goyal, S., & Cafazzo, J. A. (2020). Digital health considerations for people living with diabetes during COVID-19. *JMIR Diabetes*, 5(2), e19581. https://doi.org/10.2196/19581

Peric, S., & Stulnig, T. M. (2020). Managing diabetes in the context of COVID-19. *Wiener Klinische Wochenschrift*, 132(13-14), 356–361. https://doi.org/10.1007/s00508-020-01672-3

Bange, E., et al. (2021). CD8 T cells in COVID-19 patients: Compensating for impaired humoral immunity. *Research Square*. https://doi.org/10.21203/rs.3.rs-149173/v1

Terry, P. D., Heidel, R. E., & Dhand, R. (2021). The impact of asthma on COVID-19 outcomes: A meta-analysis. *American Journal of Respiratory and Critical Care Medicine*, 203(7), 893–905. https://doi.org/10.1164/rccm.202007-2871OC

Hussein, M. H., Elshazli, R. M., Attia, A. S., & Nguyen, T. P. (2021). Asthma and COVID-19: A meta-analysis of outcomes in patients with respiratory disease. *Journal of Asthma*. https://doi.org/10.1080/02770903.2021.1881970

Zhang, H., Han, H., He, T., Labbe, K. E., Hernandez, A. V., & Chen, H. (2021). Clinical characteristics and outcomes of COVID-19-infected cancer patients: A systematic review and meta-analysis. *JNCI Cancer Spectrum*, 113(4), djaa168. https://doi.org/10.1093/jncics/djaa168

Bange, E. et al. (2021). CD8 T cell responses in COVID-19 patients with hematologic malignancies. *Research Square*. https://doi.org/10.21203/rs.3.rs-149173/v1

Azar, W. S., Njeim, R., Fares, A. H., Azar, N. S., & El Sayed, M. (2020). The interplay between COVID-19 and diabetes: A review of the literature. *Reviews in Endocrine and Metabolic Disorders*, 21(4), 1–13. https://doi.org/10.1007/s11154-020-09573-6

Morais-Almeida, M., Pité, H., Aguiar, R., & Ansotegui, I. (2020). Asthma and COVID-19: A review of literature. *International Archives of Allergy and Immunology*, 1–9. https://doi.org/10.1159/000509057

Lovinsky-Desir, S., Deshpande, D. R., De, A., Chan, A., & Murray, L. (2020). Asthma among hospitalized COVID-19 patients: Prevalence and related outcomes. *Journal of Allergy and Clinical Immunology*, 146(5), 1027–1034.e4. https://doi.org/10.1016/j.jaci.2020.07.026

Sunjaya, A. P., Allida, S. M., Di Tanna, G. L., & Jenkins, C. (2021). Asthma and risk of severe COVID-19: A systematic review and meta-analysis. *Journal of Asthma*, 1–14. https://doi.org/10.1080/02770903.2021.1888116

Terry, P. D., Heidel, R. E., & Dhand, R. (2021). Asthma and COVID-19 in adults: A meta-analysis of prevalence and severity. *American Journal of Respiratory and Critical Care Medicine*, 203(7), 893–905. https://doi.org/10.1164/rccm.202007-2871OC

Hussein, M. H., Elshazli, R. M., Attia, A. S., & Nguyen, T. P. (2021). Asthma and COVID-19: Outcomes in patients with respiratory diseases. *Journal of Asthma*. https://doi.org/10.1080/02770903.2021.1881970

Pranata, R., Lim, M. A., Huang, I., Raharjo, S. B., & Lukito, A. A. (2020). Hypertension and COVID-19: A systematic review and meta-analysis. *Journal of Renin-Angiotensin-Aldosterone System*, 21(2), 1470320320926899. https://doi.org/10.1177/1470320320926899

Matsushita, K., Marchandot, B., Jesel, L., Ohlmann, P., & Morel, O. (2020). Cardiovascular implications of COVID-19: A comprehensive review. *Journal of Clinical Medicine*, 9(5), 1407. https://doi.org/10.3390/jcm9051407